Publication: Paraneoplastic neurological syndrome: An evolving story
1
Issued Date
2021-08-01
Resource Type
ISSN
20542585
20542577
20542577
Other identifier(s)
2-s2.0-85111869497
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Neuro-Oncology Practice. Vol.8, No.4 (2021), 362-374
Suggested Citation
Jiraporn Jitprapaikulsan, Pritikanta Paul, Smathorn Thakolwiboon, Shivam Om Mittal, Sean J. Pittock, Divyanshu Dubey Paraneoplastic neurological syndrome: An evolving story. Neuro-Oncology Practice. Vol.8, No.4 (2021), 362-374. doi:10.1093/nop/npab002 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/77996
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Paraneoplastic neurological syndrome: An evolving story
Abstract
Paraneoplastic neurological syndrome (PNS) comprises a group of neurological disorders that result from a misguided immune response to the nervous system triggered by a distant tumor. These disorders frequently manifest before the diagnosis of the underlying neoplasm. Since the first reported case in 1888 by Oppenheim, the knowledge in this area has evolved rapidly. Several classic PNS have been described, such as limbic encephalitis, paraneoplastic cerebellar degeneration, encephalomyelitis, opsoclonus-myoclonus, sensory neuronopathy, Lambert-Eaton Myasthenic syndrome, and chronic gastrointestinal dysmotility. It is now recognized that PNS can have varied nonclassical manifestations that extend beyond the traditional syndromic descriptions. Multiple onconeural antibodies with high specificity for certain tumor types and neurological phenotypes have been discovered over the past 3 decades. Increasing use of immune checkpoint inhibitors (ICIs) has led to increased recognition of neurologic ICI-related adverse events. Some of these resemble PNS. In this article, we review the clinical, oncologic, and immunopathogenic associations of PNS.